Q2 2025 marked a dynamic quarter for the healthcare and life sciences sector, highlighted by multibillion-dollar R&D collaborations, high-value M&A deals, strong venture funding, and a rebound in IPO activity. BioNTech and BMS entered a landmark $11.1 billion development and commercialization deal in June, while Pfizer partnered with 3SBio in May in a transaction valued up to $6.2 billion. AstraZeneca signed a preclinical AI-enabled research pact with CSPC Pharmaceuticals worth up to $5.3 billion.
In M&A, Sanofi acquired Blueprint Medicines for $9.5 billion, Siemens bought Dotmatics for $5.1 billion, and Torrent Pharma announced a $3 billion acquisition of JB Pharma. On the venture side, Neuralink led the quarter with a $650 million series E round in June, followed by Pathos AI’s $365 million series D and Commure’s $200 million growth financing. IPO activity also rebounded, with Caris Life Sciences raising $494 million in May, Duality Biologics securing $211 million in April in Hong Kong, and Omada Health completing a $150 million U.S. listing in May.
Global Healthcare and Life Sciences R&D Partnerships
In Q2 2025, healthcare and life sciences firms signed 144 R&D partnerships totaling $60.4 billion, with $5.2 billion paid upfront. Deal volume fell 20% from Q1, overall deal value dipped 2.6% and the upward payments dropped 13%. In contrast, Q1 saw 180 deals worth $62 billion and $6 billion upfront. Across H1 2025, firms secured 324 deals with a combined value of $122.4 billion and $11.1 billion in upfront payments.
Top R&D Partnerships in Q2 2025
BioNTech development and commercialization deal with BMS – June 2025
BioNTech granted Bristol Myers Squibb (BMS) exclusive global rights to develop and commercialize BNT-327, a bispecific antibody targeting PD-L1 and VEGF-A, for multiple solid tumors. Currently in Phase III trials for small cell and non-small cell lung cancer, BNT-327 is also slated for a Phase III trial in triple-negative breast cancer by year-end. The program will span over 20 studies across 10+ indications. BioNTech will supply the drug and retain marketing rights in the US, EU, UK, China, and Turkey, while BMS holds rights in all other markets. BioNTech receives $1.5 billion upfront, up to $2 billion in fixed payments through 2028, and may earn up to $7.6 billion in milestones.
3SBio development and commercialization deal with Pfizer – May 2025
Pfizer secured exclusive global rights (excluding China) to develop and commercialize SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors. The agreement, signed with 3SBio’s subsidiaries Shenyang Sunshine and 3S Guojian, includes an option for Pfizer to commercialize the drug in China and manufacture it in the US. 3SBio will initiate a Phase III trial in China in 2025. The deal includes a $1.3 billion upfront payment, a $100 million equity investment, and potential milestones up to $4.8 billion, plus royalties.
AstraZeneca research partnership with CSPC Pharmaceuticals – June 2025
AstraZeneca entered a preclinical-stage research collaboration with CSPC Pharmaceuticals to develop oral therapies for immunological and other chronic diseases. CSPC will lead R&D efforts in China using its AI-driven drug discovery platform. AstraZeneca holds exclusive licensing rights to the program. CSPC receives $110 million upfront and may earn up to $5.2 billion in development and sales milestones, plus single-digit royalties on future sales.
Global Healthcare and Life Sciences M&A
In Q2 2025, the healthcare and life sciences sector recorded 142 M&A’s worth $32.5 billion, with $28.4 billion paid upfront. Deal volume was essentially unchanged from Q1’s 142 transactions, yet total deal value plunged 42.3 %, and upfront cash payments shrank 34.3 % from the prior quarter’s $56.3 billion ($43.2 billion cash). For H1 2025, M&A activity reached 284 deals totaling $88.8 billion, including $71.6 billion in upfront payments.
Top M&A in Q2 2025
Sanofi acquiring Blueprint Medicines – June 2025
Sanofi announced the $9.5 billion acquisition of Blueprint Medicines, including $9.1 billion upfront and up to $400 million in milestones. The deal offers a 27% premium at $129 per share in cash. Blueprint’s portfolio includes Ayvakit, approved for various forms of systemic mastocytosis and GIST, along with late-stage candidates elenestinib (Phase III) and BLU-808 (Phase II) for allergic and inflammatory conditions. Additional assets include early-stage oncology programs targeting breast cancer and novel protein degraders.
Siemens acquiring Dotmatics – April 2025
Siemens acquired Dotmatics for $5.1 billion upfront, expanding its footprint in the life sciences sector. Dotmatics provides scientific R&D software widely used in pharma and biotech, including platforms such as GraphPad Prism, SnapGene, and Geneious. These tools support data management, analysis, and decision-making in research environments. The acquisition enhances Siemens’ Digital Industries portfolio by integrating Dotmatics’ capabilities with its AI-powered Digital Twin technologies.
Torrent Pharma acquiring JB Pharma – June 2025
Torrent Pharmaceuticals announced the acquisition of JB Pharma for approximately $3 billion, strengthening its presence in India and expanding into chronic therapies, including hypertension and ophthalmology, as well as contract development and manufacturing (CDMO). The deal includes operational synergies and enhances Torrent’s global scale-up capabilities. KKR will receive $1.4 billion for its 46.39% stake at $18.70 per share. A mandatory open offer allows public shareholders to sell up to 26% of their shares at $19.70 per share, and JB Pharma employees may divest up to 2.8% of their shares under similar terms. The transaction will be followed by a merger, with JB Pharma shareholders receiving 51 Torrent shares for every 100 JB shares.
Global Healthcare and Life Sciences Venture Activity
In Q2 2025, healthcare and life sciences venture funding reached $9.5 billion across 306 rounds, a 1% drop in deal count and a sharper 31.2% decline in capital raised compared to Q1. The previous quarter saw 309 deals totaling $13.8 billion, reflecting stronger funding earlier in the year. In total, H1 2025 recorded 615 rounds and $23.3 billion in funding.
Top Venture Funding in Q2 2025
Neuralink – Series E – $650M – June 2025
Neuralink, Elon Musk’s brain-computer interface startup, secured $650 million in a series E round to expand patient access and develop next-generation devices. The round was backed by leading investors including Sequoia Capital, Founders Fund, ARK Invest, Thrive Capital, and QIA. Neuralink’s N1 implant, featuring 1,024 electrodes across 64 ultra-thin threads, aims to enable paralyzed individuals to control digital devices using their thoughts. This brings the company’s total funding to over $1.2 billion, following a $280 million series D in August 2023.
Pathos AI – Series D – $365M – May 2025
Pathos AI secured $365 million in a series D round, boosting its valuation to approximately $1.6 billion. The funding will accelerate the development of its clinical-stage oncology pipeline and support further investment in its proprietary AI Foundation Model. Pathos is building the largest multimodal foundation model in oncology, integrating clinical, molecular, and imaging data to enhance asset selection, trial design, biomarker discovery, and therapeutic development.
Commure – Series Unspecified – $200M – June 2025
Commure raised $200 million in non-dilutive growth financing from General Catalyst’s Customer Value Fund to support rising demand for its AI-powered healthcare infrastructure platform. The company’s solutions span revenue cycle management, ambient AI clinical documentation, and practice management. Proceeds will fuel product development, implementation, and go-to-market expansion, enabling health systems to drive measurable clinical and financial outcomes.
Global Healthcare and Life Sciences IPO Activity
In Q2 2025, 10 healthcare and life sciences companies went public, raising $1.4 billion, a 25% increase in IPO count but no change in proceeds compared to Q1’s 8 listings totaling $1.4 billion. Overall, in H1 2025, 18 IPOs raised $2.6 billion.
Top IPOs in Q2 2025
Caris Life Sciences – IPO – $494.1M – May 2025
Caris Life Sciences, a precision oncology company, raised approximately $494 million in its IPO, valuing it at around $5.9 billion. Trading under the ticker “CA” on NASDAQ, Caris issued over 23.5 million shares, with underwriters granted a 30-day option to purchase an additional 3.5 million shares. The company increased its IPO price range to $19–$20 per share, up from $16–$18. The IPO follows a $168 million growth round in April, bringing Caris’ total capital raised since 2018 to $1.9 billion. Caris leverages whole-exome and transcriptome sequencing alongside advanced AI and ML to power a multimodal platform for molecular diagnostics and cancer treatment.
DualityBio – IPO – $211M – April 2025
Duality Biologics (DualityBio), backed by BioNTech, a clinical-stage biotech focused on next-generation antibody-drug conjugates for cancer and autoimmune diseases, raised HK$1.6 billion ($210 million) in its global IPO. The company offered 17.33 million shares at HK$94.60 (USD $12.30) per share and began trading on the Hong Kong Stock Exchange under the ticker 9606 on April 15, 2025. Morgan Stanley, Jefferies, and CITIC Securities/CLSA acted as joint sponsors and global coordinators, alongside CICC, CMBI, ICBCI, BOCI, GFSHK, and ABCI. Cooley LLP served as legal advisor to the underwriters.
Omada Health – IPO – $150.1M – May 2025
Omada Health, a virtual chronic care provider, raised $150 million in its U.S. IPO by offering 7.9 million shares at $19 each, pricing in the middle of its $18–$20 range. Shares will begin trading on Nasdaq under the ticker “OMDA” on Friday. Founded in 2012, Omada delivers virtual care programs for chronic conditions such as prediabetes, diabetes, and hypertension. Its “between-visit” care model is designed to supplement traditional healthcare delivery.
Also check out Global Healthcare and Life Sciences – Q1 2025 Review
